Drug intelligence / Profile preview

LEAF-1701

Development stage: Preclinical
Lead developer: LEAF Pharmaceuticals
Modality: Small Molecules

Overview

LEAF-1701 is a small molecule anticancer drug developed by L.E.A.F. Pharmaceuticals. It acts as an antagonist of folate receptor alpha (FOLR1), targeting tumor-mediated metabolic dysregulation associated with cancer and the immune system. LEAF-1701 belongs to a new generation of onco-immuno antimetabolites designed to disrupt dysregulated serine-glycine one-carbon metabolism in cancer cells, aiming to inhibit tumor growth while sparing normal cells. Preclinical studies have shown that it is more potent than pemetrexed in various cell lines, with improved selectivity for malignant over normal tissues[1][2][4].

Other names: liposomal alpha-L pentaglutamated antifolatenanoliposomal alpha-L pentaglutamated antifolateliposomal polyglutamated pemetrexed analog

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on LEAF-1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAF-1701.

Explore the full profile